vs

Side-by-side financial comparison of Accel Entertainment, Inc. (ACEL) and Lantheus Holdings, Inc. (LNTH). Click either name above to swap in a different company.

Lantheus Holdings, Inc. is the larger business by last-quarter revenue ($406.8M vs $341.4M, roughly 1.2× Accel Entertainment, Inc.). Lantheus Holdings, Inc. runs the higher net margin — 13.3% vs 4.7%, a 8.6% gap on every dollar of revenue. On growth, Accel Entertainment, Inc. posted the faster year-over-year revenue change (7.5% vs 4.0%). Over the past eight quarters, Accel Entertainment, Inc.'s revenue compounded faster (5.0% CAGR vs 4.9%).

Legendary Entertainment, LLC is an American mass media and film production company based in Burbank, California, founded by Thomas Tull in 2000. The company has often collaborated with the major studios, including Warner Bros. Pictures, Universal Pictures, Sony Pictures and Paramount Pictures, as well as streaming services such as Netflix and Hulu.

Lantheus Holdings, Inc. is a global healthcare firm specializing in the development, manufacturing and commercialization of innovative diagnostic imaging agents and related solutions. Its offerings cover core medical segments including oncology, cardiology and urology, with primary markets across North America and other key global regions.

ACEL vs LNTH — Head-to-Head

Bigger by revenue
LNTH
LNTH
1.2× larger
LNTH
$406.8M
$341.4M
ACEL
Growing faster (revenue YoY)
ACEL
ACEL
+3.5% gap
ACEL
7.5%
4.0%
LNTH
Higher net margin
LNTH
LNTH
8.6% more per $
LNTH
13.3%
4.7%
ACEL
Faster 2-yr revenue CAGR
ACEL
ACEL
Annualised
ACEL
5.0%
4.9%
LNTH

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ACEL
ACEL
LNTH
LNTH
Revenue
$341.4M
$406.8M
Net Profit
$16.1M
$54.1M
Gross Margin
59.2%
Operating Margin
8.7%
19.0%
Net Margin
4.7%
13.3%
Revenue YoY
7.5%
4.0%
Net Profit YoY
91.7%
558.8%
EPS (diluted)
$0.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACEL
ACEL
LNTH
LNTH
Q1 26
$341.4M
Q4 25
$341.4M
$406.8M
Q3 25
$329.7M
$384.0M
Q2 25
$335.9M
$378.0M
Q1 25
$323.9M
$372.8M
Q4 24
$317.5M
$391.1M
Q3 24
$302.2M
$378.7M
Q2 24
$309.4M
$394.1M
Net Profit
ACEL
ACEL
LNTH
LNTH
Q1 26
$16.1M
Q4 25
$16.2M
$54.1M
Q3 25
$13.4M
$27.8M
Q2 25
$7.3M
$78.8M
Q1 25
$14.6M
$72.9M
Q4 24
$8.4M
$-11.8M
Q3 24
$4.9M
$131.1M
Q2 24
$14.6M
$62.1M
Gross Margin
ACEL
ACEL
LNTH
LNTH
Q1 26
Q4 25
59.2%
Q3 25
57.9%
Q2 25
63.8%
Q1 25
63.8%
Q4 24
63.5%
Q3 24
63.9%
Q2 24
64.9%
Operating Margin
ACEL
ACEL
LNTH
LNTH
Q1 26
8.7%
Q4 25
8.7%
19.0%
Q3 25
7.7%
11.4%
Q2 25
8.0%
23.3%
Q1 25
8.0%
27.4%
Q4 24
6.5%
29.1%
Q3 24
7.2%
35.3%
Q2 24
7.3%
26.1%
Net Margin
ACEL
ACEL
LNTH
LNTH
Q1 26
4.7%
Q4 25
4.7%
13.3%
Q3 25
4.1%
7.2%
Q2 25
2.2%
20.8%
Q1 25
4.5%
19.6%
Q4 24
2.6%
-3.0%
Q3 24
1.6%
34.6%
Q2 24
4.7%
15.8%
EPS (diluted)
ACEL
ACEL
LNTH
LNTH
Q1 26
Q4 25
$0.19
$0.86
Q3 25
$0.16
$0.41
Q2 25
$0.08
$1.12
Q1 25
$0.17
$1.02
Q4 24
$0.09
$-0.18
Q3 24
$0.06
$1.79
Q2 24
$0.17
$0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACEL
ACEL
LNTH
LNTH
Cash + ST InvestmentsLiquidity on hand
$296.6M
$359.1M
Total DebtLower is stronger
$568.7M
Stockholders' EquityBook value
$269.7M
$1.1B
Total Assets
$1.1B
$2.2B
Debt / EquityLower = less leverage
0.52×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACEL
ACEL
LNTH
LNTH
Q1 26
$296.6M
Q4 25
$296.6M
$359.1M
Q3 25
$290.2M
$382.0M
Q2 25
$264.6M
$695.6M
Q1 25
$271.9M
$938.5M
Q4 24
$281.3M
$912.8M
Q3 24
$265.1M
$866.4M
Q2 24
$254.9M
$757.0M
Total Debt
ACEL
ACEL
LNTH
LNTH
Q1 26
Q4 25
$607.4M
$568.7M
Q3 25
$595.4M
$567.9M
Q2 25
$595.5M
$566.8M
Q1 25
$580.7M
$566.1M
Q4 24
$595.4M
$565.3M
Q3 24
$554.1M
$613.0K
Q2 24
$565.7M
$563.2M
Stockholders' Equity
ACEL
ACEL
LNTH
LNTH
Q1 26
$269.7M
Q4 25
$269.7M
$1.1B
Q3 25
$267.1M
$1.1B
Q2 25
$260.5M
$1.2B
Q1 25
$259.1M
$1.2B
Q4 24
$255.0M
$1.1B
Q3 24
$206.7M
$1.2B
Q2 24
$209.1M
$1.0B
Total Assets
ACEL
ACEL
LNTH
LNTH
Q1 26
$1.1B
Q4 25
$1.1B
$2.2B
Q3 25
$1.1B
$2.3B
Q2 25
$1.1B
$2.1B
Q1 25
$1.0B
$2.1B
Q4 24
$1.0B
$2.0B
Q3 24
$950.2M
$2.0B
Q2 24
$950.3M
$1.9B
Debt / Equity
ACEL
ACEL
LNTH
LNTH
Q1 26
Q4 25
2.25×
0.52×
Q3 25
2.23×
0.51×
Q2 25
2.29×
0.49×
Q1 25
2.24×
0.49×
Q4 24
2.33×
0.52×
Q3 24
2.68×
0.00×
Q2 24
2.71×
0.55×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACEL
ACEL
LNTH
LNTH
Operating Cash FlowLast quarter
$150.9M
$90.2M
Free Cash FlowOCF − Capex
$81.4M
FCF MarginFCF / Revenue
20.0%
Capex IntensityCapex / Revenue
2.2%
Cash ConversionOCF / Net Profit
9.38×
1.67×
TTM Free Cash FlowTrailing 4 quarters
$354.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACEL
ACEL
LNTH
LNTH
Q1 26
$150.9M
Q4 25
$31.1M
$90.2M
Q3 25
$55.2M
$105.3M
Q2 25
$19.8M
$87.1M
Q1 25
$44.8M
$107.6M
Q4 24
$13.5M
$157.7M
Q3 24
$50.1M
$175.1M
Q2 24
$28.9M
$84.7M
Free Cash Flow
ACEL
ACEL
LNTH
LNTH
Q1 26
Q4 25
$16.0M
$81.4M
Q3 25
$34.2M
$94.7M
Q2 25
$-6.2M
$79.1M
Q1 25
$18.0M
$98.8M
Q4 24
$2.1M
$141.4M
Q3 24
$33.1M
$159.3M
Q2 24
$11.4M
$73.5M
FCF Margin
ACEL
ACEL
LNTH
LNTH
Q1 26
Q4 25
4.7%
20.0%
Q3 25
10.4%
24.7%
Q2 25
-1.9%
20.9%
Q1 25
5.6%
26.5%
Q4 24
0.7%
36.1%
Q3 24
11.0%
42.0%
Q2 24
3.7%
18.7%
Capex Intensity
ACEL
ACEL
LNTH
LNTH
Q1 26
Q4 25
4.4%
2.2%
Q3 25
6.4%
2.8%
Q2 25
7.8%
2.1%
Q1 25
8.3%
2.3%
Q4 24
3.6%
4.2%
Q3 24
5.6%
4.2%
Q2 24
5.7%
2.8%
Cash Conversion
ACEL
ACEL
LNTH
LNTH
Q1 26
9.38×
Q4 25
1.92×
1.67×
Q3 25
4.13×
3.79×
Q2 25
2.71×
1.11×
Q1 25
3.06×
1.47×
Q4 24
1.62×
Q3 24
10.23×
1.34×
Q2 24
1.98×
1.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACEL
ACEL

Illinois$245.2M72%
Montana (1)$42.6M12%
Nevada$28.0M8%
Nebraska$9.6M3%
Louisiana$9.5M3%
Georgia$5.7M2%

LNTH
LNTH

Radiopharmaceutical Oncology$240.2M59%
Definity$85.3M21%
Strategic Partnerships And Other$23.3M6%
Techne Lite$21.0M5%
Licenseand Royalty Revenues$17.4M4%
Other$13.6M3%
Other Precision Diagnostics$5.9M1%

Related Comparisons